Hi Olive, Yes the test is the goods no doubt.Just a matter of sitting back now and watching the share price increase with sales.First cab of the rank would have to be the AFEB.A lot of the FDA data came from the forces and coupled with the contract for lieshman disease Cellestis an important piece of their strategy.So much good news to come its odd the sellers are at play. I think some of the instos have taken the 60c of late and the average punter has been as well.Big mistake but each to their own. c.c.c
CST Price at posting:
0.0¢ Sentiment: None Disclosure: Not Held
